<DOC>
	<DOC>NCT01476280</DOC>
	<brief_summary>Ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor antagonists and this randomized double blind study was designed to compare efficacy of ramosetron and palonosetron to prevent postoperative nausea and vomiting. Investigator hypothesized that palonosetron would have stronger and longer lasting antiemetic effect compared with ramosetron and evaluated the patients for the first 48 hours after surgery.</brief_summary>
	<brief_title>Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea and Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>ASA Physical Status 1 or 2 Elective gynaecological laparoscopic surgery of â‰¥ 1h duration Antiemetics, steroids, or psychoactive medications within 24 h of study initiation Vomiting or retching in the 24 h preceding surgery Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry Ongoing vomiting from gastrointestinal disease</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>antiemetics</keyword>
	<keyword>ramosetron</keyword>
	<keyword>palonosetron</keyword>
	<keyword>PONV(postoperative nausea and vomiting)</keyword>
</DOC>